Display options
Cite
Kadry Z, Bronsther O, Van Thiel DH, et al. Kaposi's sarcoma in two primary liver allograft recipients occurring under FK506 immunosuppression. Clin Transplant. 1993;7:188-194
Kadry, Z., Bronsther, O., Van Thiel, D. H., Randhawa, P., Fung, J. J., & Starzl, T. E. (1993). Kaposi's sarcoma in two primary liver allograft recipients occurring under FK506 immunosuppression. Clinical transplantation, 7188-194.
Kadry, Zaklyah, et al. "Kaposi's sarcoma in two primary liver allograft recipients occurring under FK506 immunosuppression." Clinical transplantation vol. 7 (1993): 188-194.
Kadry Z, Bronsther O, Van Thiel DH, Randhawa P, Fung JJ, Starzl TE. Kaposi's sarcoma in two primary liver allograft recipients occurring under FK506 immunosuppression. Clin Transplant. 1993 Jan 01;7:188-194. PMID: 21170290; PMCID: PMC3002425.
Copy Download .nbib Format: NLM
Share it on

Clin Transplant. 1993 Jan 01;7:188-194.

Kaposi's sarcoma in two primary liver allograft recipients occurring under FK506 immunosuppression.

Clinical transplantation

Zaklyah Kadry, Oscar Bronsther, David H Van Thiel, Parmjeet Randhawa, John J Fung, Thomas E Starzl

Affiliations

  1. Pittsburgh Transplant Institute, Departments of Surgery, University of Pittsburgh Health and Science Center, Pittsburgh, PA.

PMID: 21170290 PMCID: PMC3002425

Abstract

Of 1463 liver allograft recipients receiving the combination of FK506 and steroids as their primary immunosuppressive regimen, 2 patients developed Kaposi's sarcoma. Although previously described as a complication of organ transplantation, this is the first case report of Kaposi's sarcoma occurring in association with the macrolide immunosuppressive agent FK506. A discussion of the clinical presentation and course of Kaposi's sarcoma in these 2 patients, as well as a review of the past literature on Kaposi's sarcoma in organ transplant recipients, emphasizes the therapeutic difficulties encountered. Kaposi's sarcoma is also compared to lymphoproliferative disorders, another well-recognized complication of immunosuppression, highlighting the differences between these two entities.

References

  1. Hematol Oncol Clin North Am. 1991 Apr;5(2):311-22 - PubMed
  2. Curr Probl Surg. 1988 Jun;25(6):367-472 - PubMed
  3. Hematol Oncol Clin North Am. 1991 Apr;5(2):281-95 - PubMed
  4. Proc Natl Acad Sci U S A. 1990 Jun;87(11):4068-72 - PubMed
  5. Crit Rev Oncol Hematol. 1991;11(2):87-107 - PubMed
  6. Semin Oncol. 1987 Jun;14(2 Suppl 3):27-33 - PubMed
  7. Transplantation. 1979 Jan;27(1):8-11 - PubMed
  8. Semin Oncol. 1987 Jun;14(2 Suppl 3):13-8 - PubMed
  9. Transplant Proc. 1989 Feb;21(1 Pt 3):3197-8 - PubMed
  10. Lancet. 1975 Oct 11;2(7937):687-9 - PubMed
  11. Proc Natl Acad Sci U S A. 1983 Aug;80(15):4861-4 - PubMed
  12. Lancet. 1992 Feb 29;339(8792):515-8 - PubMed
  13. Cancer. 1990 Feb 1;65(3):492-8 - PubMed
  14. Transplant Proc. 1991 Feb;23(1 Pt 2):1101-3 - PubMed
  15. Hematol Oncol Clin North Am. 1991 Apr;5(2):297-310 - PubMed
  16. Transplant Proc. 1991 Dec;23(6):3044-6 - PubMed
  17. Ann Intern Med. 1990 Jun 1;112(11):812-21 - PubMed
  18. Am J Med. 1988 Feb;84(2):225-32 - PubMed
  19. Int J Cancer. 1975 May 15;15(5):839-48 - PubMed
  20. N Engl J Med. 1992 May 28;326(22):1456-63 - PubMed
  21. Cancer Res. 1987 Oct 1;47(19):5155-61 - PubMed
  22. Transplant Proc. 1991 Feb;23(1 Pt 2):1438-9 - PubMed
  23. Curr Opin Oncol. 1991 Apr;3(2):377-83 - PubMed
  24. Cancer. 1991 Sep 15;68(6):1361-4 - PubMed
  25. Eur J Cancer Clin Oncol. 1988 Jun;24(6):973-8 - PubMed

Publication Types

Grant support